(Q33877411)

English

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ductal carcinoma

1 reference

based on heuristic

inferred from title

15

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sunil R. Lakhani

14

object named as

S R Lakhani

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

D Generali

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

F M Buffa

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

S Deb

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

M Cummings

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

L E Reid

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

M Taylor

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

D Andreis

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

G Allevi

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

G Ferrero

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

D Byrne

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

M Martinotti

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A Bottini

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A L Harris

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

29 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

46-54

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Heterogeneity of ductal carcinoma in situ and its effects on management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Ductal carcinoma in situ, complexities and challenges.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

5 July 2018

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090726

29 October 2018

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

21 January 2018

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24874483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24874483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting recommendations for tumor marker prognostic studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24874483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Gro

1 reference

https://pubmed.ncbi.nlm.nih.gov/24874483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regularization and variable selection via the elastic net

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BJC.2014.236

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33877411&oldid=2195918169"